Biotech Bullish Stocks: Oxygen Biotherapeutics (NASDAQ:OXBT), MediciNov. (NASDAQ:MNOV), Celladon Corp (NASDAQ:CLDN), Epizyme (NASDAQ:EPZM)

Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) announced Monday that it has written U.S. Food and Drug Administration confirmation that a clinical hold has been removed on development of its treatment for traumatic brain injury, decompression sickness and stroke. Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) shares after opening at $5.26 moved to $5.55 on last trade day and at the end of the day closed at $5.53. Company price to sales ratio in past twelve months was calculated as 513.00 and price to cash ratio as 61.56. Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) showed a negative weekly performance of -1.60%.

MediciNova, Inc. (NASDAQ:MNOV) a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), yesterday announced the appointment of Mr. Yoshio Ishizaka to its Board of Directors. MediciNova, Inc. (NASDAQ:MNOV) shares advanced 9.04% in last trading session and ended the day on $2.05. MNOV return on equity ratio is recorded as -53.30% and its return on assets is -42.50%. MediciNova, Inc. (NASDAQ:MNOV) yearly performance is -12.77%.

Celadon Group (NASDAQ:CLDN) said it has agreed to sell about 600 leases and tractors to Element Financial Corp. for about $53 million to pay down debt. Celladon Corp (NASDAQ:CLDN) shares moved up 13.90% in last trading session and was closed at $10.49, while trading in range of $9.07 – $10.50. Celladon Corp (NASDAQ:CLDN) year to date (YTD) performance is -16.35%.

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced yesterday that the U.S. Patent and Trademark Office has granted U.S. Patent No. 8,691,507 with claims that cover the identification of patients carrying EZH2 oncogenic mutations as candidates for treatment with EZH2 inhibitors. Epizyme Inc. (NASDAQ:EPZM) weekly performance is -7.88%. On last trading day company shares ended up $21.85. Epizyme Inc. (NASDAQ:EPZM) distance from 50-day simple moving average (SMA50) is -22.59%. Analysts mean target price for the company is $42.50.